🔗 Share this article WHO Issues Warning Over Severe Shortage of Obesity Injections Under 10% of people eligible to benefit from weight-loss injections like Wegovy can access them, caution the global health agency as it issues its initial guidance on the therapies. Considering more than one billion individuals worldwide now living with obesity, it is advocating for more widespread and fairer access to this class of drugs. According to forecasts, over two billion are projected to be living with obesity by 2030 without intervention. "The latest guidelines affirms that excess weight is a long-term condition that can be managed with thorough and continuous care," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are major hurdles to universal availability to the injections that can help people shift substantial body mass, notes the organization. GLP-1 Therapy Scarcity Even under the present most optimistic outlook, the production of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization. The recommendation calls on countries and companies to expand availability, through strategies like voluntary licensing. The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is set to lapse in several countries in 2026. How Weight-Loss Jabs Operate These medications mimick a body's own hormone to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake. Individuals commonly see weight reduction within a few weeks of commencing the regular doses. Evidence points to people may regain a significant portion a year later of discontinuing the treatment, when their typical food cravings return. Being carrying excess weight raises your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
Under 10% of people eligible to benefit from weight-loss injections like Wegovy can access them, caution the global health agency as it issues its initial guidance on the therapies. Considering more than one billion individuals worldwide now living with obesity, it is advocating for more widespread and fairer access to this class of drugs. According to forecasts, over two billion are projected to be living with obesity by 2030 without intervention. "The latest guidelines affirms that excess weight is a long-term condition that can be managed with thorough and continuous care," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are major hurdles to universal availability to the injections that can help people shift substantial body mass, notes the organization. GLP-1 Therapy Scarcity Even under the present most optimistic outlook, the production of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization. The recommendation calls on countries and companies to expand availability, through strategies like voluntary licensing. The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is set to lapse in several countries in 2026. How Weight-Loss Jabs Operate These medications mimick a body's own hormone to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake. Individuals commonly see weight reduction within a few weeks of commencing the regular doses. Evidence points to people may regain a significant portion a year later of discontinuing the treatment, when their typical food cravings return. Being carrying excess weight raises your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.